Literature DB >> 2582411

Human T-lymphocyte response in vitro to synthetic peptides of herpes simplex virus glycoprotein D.

E C DeFreitas, B Dietzschold, H Koprowski.   

Abstract

Immunization of mice with a synthetic peptide that corresponds to a murine antibody-defined immunodominant domain of herpes simplex virus (HSV) glycoprotein D (gD) induced neutralizing antibodies against HSV types 1 and 2 and protected animals against a lethal challenge with HSV type 2 (Dietzschold, B., Eisenberg, R., Ponce de Leon, M., Golub, E., Hudecz, F., Varicchio, A. & Cohen, G. (1984) J. Virol. 52, 431-435). We report here that human peripheral blood T cells from HSV-seropositive and -seronegative adult donors are activated by this synthetic peptide in vitro. Interleukin-2-dependent T-cell lines established from these cultures respond specifically to peptides containing residues 1-23 of HSV gD and to a panel of overlapping peptides within this domain. The T-cell proliferative response was maximal when the majority of interleukin-2-propagated T cells were of the helper phenotype and the peptides were at least 16 amino acids long. Peptides of 8 or 12 amino acids from the carboxyl terminus were nonstimulatory. Peptide-activated T-cell lines from sero-negative donors less than 11 years old could be established in vitro, but most cells were of the suppressor/cytotoxic phenotype and demonstrated no antigen-specificity when tested with the panel of synthetic peptides.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2582411      PMCID: PMC397788          DOI: 10.1073/pnas.82.10.3425

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Membrane proteins specified by herpes simplex viruses. I. Identification of four glycoprotein precursors and their products in type 1-infected cells.

Authors:  P G Spear
Journal:  J Virol       Date:  1976-03       Impact factor: 5.103

2.  Induction of plaque-forming cells in cultured human lymphocytes by combined action of antigen and EB virus.

Authors:  A L Luzzati; H Hengartner; M H Schreier
Journal:  Nature       Date:  1977-09-29       Impact factor: 49.962

3.  Fluorescence-activated cell sorting of human T and B lymphocytes. II. Identification of the cell type responsible for interferon production and cell proliferation in response to mitogens.

Authors:  L B Epstein; H W Kreth; L A Herzenberg
Journal:  Cell Immunol       Date:  1974-06       Impact factor: 4.868

4.  Fine structure analysis of type-specific and type-common antigenic sites of herpes simplex virus glycoprotein D.

Authors:  B Dietzschold; R J Eisenberg; M Ponce de Leon; E Golub; F Hudecz; A Varrichio; G H Cohen
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

5.  Primary in vitro antibody response from human peripheral blood lymphocytes.

Authors:  J F Delfraissy; P Galanaud; J Dormont; C Wallon
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

6.  Herpes simplex vaccines.

Authors:  M R Hilleman
Journal:  Cancer Res       Date:  1976-02       Impact factor: 12.701

7.  Isolation of a herpes simplex virus-specific antigenic fraction which stimulates the production of neutralizing antibody.

Authors:  G H Cohen; M Ponce de Leon; C Nichols
Journal:  J Virol       Date:  1972-11       Impact factor: 5.103

Review 8.  Immunology of herpes simplex virus infection: relevance to herpes simplex virus vaccines and cervical cancer.

Authors:  A J Nahmias; S L Shore; S Kohl; S E Starr; R B Ashman
Journal:  Cancer Res       Date:  1976-02       Impact factor: 12.701

9.  Direct microsequence analysis of polypeptides using an improved sequenator, a nonprotein carrier (polybrene), and high pressure liquid chromatography.

Authors:  M W Hunkapiller; L E Hood
Journal:  Biochemistry       Date:  1978-05-30       Impact factor: 3.162

10.  Activation of human B lymphocytes. I. Direct plaque-forming cell assay for the measurement of polyclonal activation and antigenic stimulation of human B lymphocytes.

Authors:  A S Fauci; K R Pratt
Journal:  J Exp Med       Date:  1976-09-01       Impact factor: 14.307

View more
  17 in total

1.  Fine mapping of antigenic site II of herpes simplex virus glycoprotein D.

Authors:  V J Isola; R J Eisenberg; G R Siebert; C J Heilman; W C Wilcox; G H Cohen
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

2.  Mapping an antibody-binding site and a T-cell-stimulating site on the 1A protein of respiratory syncytial virus.

Authors:  J A Nicholas; M A Mitchell; M E Levely; K L Rubino; J H Kinner; N K Harn; C W Smith
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

3.  Regulation of interleukin 2 receptors on T cells from multiple sclerosis patients.

Authors:  E C DeFreitas; M Sandberg-Wollheim; K Schonely; M Boufal; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

4.  Cells expressing herpes simplex virus glycoprotein gC but not gB, gD, or gE are recognized by murine virus-specific cytotoxic T lymphocytes.

Authors:  K L Rosenthal; J R Smiley; S South; D C Johnson
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

5.  Native and recombinant herpes simplex virus type 1 envelope proteins induce human immune T-lymphocyte responses.

Authors:  J W Torseth; G H Cohen; R J Eisenberg; P W Berman; L A Lasky; C P Cerini; C J Heilman; S Kerwar; T C Merigan
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

6.  Influence of peptide acylation, liposome incorporation, and synthetic immunomodulators on the immunogenicity of a 1-23 peptide of glycoprotein D of herpes simplex virus: implications for subunit vaccines.

Authors:  K Brynestad; B Babbit; L Huang; B T Rouse
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

7.  Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D.

Authors:  Xiuli Zhang; Florence A Castelli; Xiaoming Zhu; Michele Wu; Bernard Maillère; Lbachir BenMohamed
Journal:  Clin Vaccine Immunol       Date:  2008-07-30

8.  Liposomal gD ectodomain (gD1-306) vaccine protects against HSV2 genital or rectal infection of female and male mice.

Authors:  K Olson; P Macias; S Hutton; W A Ernst; G Fujii; J P Adler-Moore
Journal:  Vaccine       Date:  2009-10-14       Impact factor: 3.641

9.  Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity.

Authors:  Lbachir BenMohamed; Georges Bertrand; Cory D McNamara; Helene Gras-Masse; Juergen Hammer; Steven L Wechsler; Anthony B Nesburn
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  Immunodominant epitopes in herpes simplex virus type 2 glycoprotein D are recognized by CD4 lymphocytes from both HSV-1 and HSV-2 seropositive subjects.

Authors:  Min Kim; Janette Taylor; John Sidney; Zorka Mikloska; Neil Bodsworth; Katerina Lagios; Heather Dunckley; Karen Byth-Wilson; Martine Denis; Robert Finlayson; Rajiv Khanna; Alessandro Sette; Anthony L Cunningham
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.